# TAO Synergies Inc.: financial statements, quarterly

TAOX · Nasdaq · CIK 1571934 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/taox.md) · [Financials](/companies/taox/financials.md) · [Filings](/companies/taox/filings.md) · [Insiders](/companies/taox/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/taox/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001104659-26-095966.md) | [0.2](/filings/0001104659-25-112570.md) | [0.1 d](/filings/0001104659-26-070987.md) | [0.4](/filings/0001104659-26-060353.md) | [0.1](/filings/0001104659-26-095966.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001104659-26-060353.md) | [0.0](/filings/0001104659-26-095966.md) |
| Research and development | $m | [0.2](/filings/0001410578-24-001891.md) | [0.6 d](/filings/0001410578-25-000518.md) | [0.6](/filings/0001410578-25-001327.md) | [0.3](/filings/0001410578-25-001820.md) | [0.2](/filings/0001104659-25-112570.md) | [0.4 d](/filings/0001104659-26-070987.md) | [0.1](/filings/0001104659-26-060353.md) | [0.1](/filings/0001104659-26-095966.md) | [0.1](/filings/0001104659-25-112570.md) | [0.1 d](/filings/0001104659-26-070987.md) | [0.0](/filings/0001104659-26-060353.md) | [0.0](/filings/0001104659-26-095966.md) |
| Operating income | $m | not reported | not reported | not reported | [(1.6)](/filings/0001410578-25-001820.md) | [(2.0)](/filings/0001104659-25-112570.md) | [(1.6) d](/filings/0001104659-26-070987.md) | [(1.1)](/filings/0001104659-26-060353.md) | [(3.0)](/filings/0001104659-26-095966.md) | [(1.8)](/filings/0001104659-25-112570.md) | [(3.1) d](/filings/0001104659-26-070987.md) | [(1.3)](/filings/0001104659-26-060353.md) | [(1.6)](/filings/0001104659-26-095966.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001104659-26-060353.md) | [0.0](/filings/0001104659-26-095966.md) | not reported | not reported | [0.0](/filings/0001104659-26-060353.md) | [0.0](/filings/0001104659-26-095966.md) |
| Net income | $m | [0.8](/filings/0001410578-24-001891.md) | [(1.0) d](/filings/0001410578-25-000518.md) | [(0.2)](/filings/0001410578-25-001327.md) | [(1.3)](/filings/0001410578-25-001820.md) | [(5.7)](/filings/0001104659-25-112570.md) | [(5.5) d](/filings/0001104659-26-070987.md) | [0.4](/filings/0001104659-26-060353.md) | [(17.5)](/filings/0001104659-26-095966.md) | [(3.9)](/filings/0001104659-25-112570.md) | [(7.7) d](/filings/0001104659-26-070987.md) | [4.3](/filings/0001104659-26-060353.md) | [(9.3)](/filings/0001104659-26-095966.md) |
| Diluted EPS | $ per share | [0.84](/filings/0001410578-24-001891.md) | not reported | [(0.41)](/filings/0001410578-25-001327.md) | [(1.18)](/filings/0001410578-25-001820.md) | [(5.01)](/filings/0001104659-25-112570.md) | not reported | [0.04](/filings/0001104659-26-060353.md) | [(11.26)](/filings/0001104659-26-095966.md) | [(1.56)](/filings/0001104659-25-112570.md) | not reported | [0.43](/filings/0001104659-26-060353.md) | [(1.83)](/filings/0001104659-26-095966.md) |
| Basic EPS | $ per share | [0.84](/filings/0001410578-24-001891.md) | not reported | [(0.41)](/filings/0001410578-25-001327.md) | [(1.18)](/filings/0001410578-25-001820.md) | [(5.01)](/filings/0001104659-25-112570.md) | not reported | [0.12](/filings/0001104659-26-060353.md) | [(11.26)](/filings/0001104659-26-095966.md) | [(1.56)](/filings/0001104659-25-112570.md) | not reported | [0.45](/filings/0001104659-26-060353.md) | [(1.83)](/filings/0001104659-26-095966.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [31.7](/filings/0001410578-23-002492.md) | [28.7](/filings/0001410578-25-000518.md) | [26.3](/filings/0001410578-24-000887.md) | [25.0](/filings/0001410578-24-001448.md) | [19.6](/filings/0001410578-24-001891.md) | [17.7](/filings/0001104659-26-070987.md) | [14.8](/filings/0001410578-25-001327.md) | [14.4](/filings/0001410578-25-001820.md) | not reported | [5.5](/filings/0001104659-26-095966.md) | [3.6](/filings/0001104659-26-060353.md) | [2.4](/filings/0001104659-26-095966.md) |
| Current assets | $m | [32.3](/filings/0001410578-23-002492.md) | [30.5](/filings/0001410578-25-000518.md) | [28.8](/filings/0001410578-24-000887.md) | [27.8](/filings/0001410578-24-001448.md) | [22.3](/filings/0001410578-24-001891.md) | [17.7](/filings/0001104659-26-070987.md) | [15.3](/filings/0001410578-25-001327.md) | [19.8](/filings/0001410578-25-001820.md) | [18.3](/filings/0001104659-25-112570.md) | [25.4](/filings/0001104659-26-095966.md) | [30.2](/filings/0001104659-26-060353.md) | [20.6](/filings/0001104659-26-095966.md) |
| Total assets | $m | [32.4](/filings/0001410578-23-002492.md) | [31.1](/filings/0001410578-25-000518.md) | [29.4](/filings/0001410578-24-000887.md) | [28.4](/filings/0001410578-24-001448.md) | [22.8](/filings/0001410578-24-001891.md) | [17.7](/filings/0001104659-26-070987.md) | [15.3](/filings/0001410578-25-001327.md) | [19.8](/filings/0001410578-25-001820.md) | [18.4](/filings/0001104659-25-112570.md) | [25.8](/filings/0001104659-26-095966.md) | [31.0](/filings/0001104659-26-060353.md) | [21.1](/filings/0001104659-26-095966.md) |
| Current liabilities | $m | [1.8](/filings/0001410578-23-002492.md) | [4.3](/filings/0001410578-25-000518.md) | [6.3](/filings/0001410578-24-000887.md) | [9.4](/filings/0001410578-24-001448.md) | [0.3](/filings/0001410578-24-001891.md) | [1.0](/filings/0001104659-26-070987.md) | [0.2](/filings/0001410578-25-001327.md) | [1.0](/filings/0001410578-25-001820.md) | [1.0](/filings/0001104659-25-112570.md) | [1.8](/filings/0001104659-26-095966.md) | [1.1](/filings/0001104659-26-060353.md) | [1.0](/filings/0001104659-26-095966.md) |
| Total liabilities | $m | [3.9](/filings/0001410578-23-002492.md) | [5.5](/filings/0001410578-25-000518.md) | [6.5](/filings/0001410578-24-000887.md) | [9.6](/filings/0001410578-24-001448.md) | [9.7](/filings/0001410578-24-001891.md) | [11.0](/filings/0001104659-26-070987.md) | [8.9](/filings/0001410578-25-001327.md) | [1.8](/filings/0001410578-25-001820.md) | [1.7](/filings/0001104659-25-112570.md) | [3.9](/filings/0001104659-26-095966.md) | [4.9](/filings/0001104659-26-060353.md) | [3.8](/filings/0001104659-26-095966.md) |
| Shareholders' equity | $m | [26.7](/filings/0001410578-24-001891.md) | [24.3](/filings/0001104659-26-070987.md) | [22.1](/filings/0001410578-25-001820.md) | [18.8](/filings/0001104659-25-112570.md) | [12.8](/filings/0001104659-25-112570.md) | [5.9](/filings/0001104659-26-095966.md) | [5.2](/filings/0001104659-26-095966.md) | [17.2](/filings/0001104659-26-095966.md) | [16.1](/filings/0001104659-25-112570.md) | [21.1](/filings/0001104659-26-095966.md) | [23.3](/filings/0001104659-26-095966.md) | [12.7](/filings/0001104659-26-095966.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,172) d](/filings/0001410578-24-001891.md) | [(1,066) d](/filings/0001410578-25-000518.md) | [(1,832)](/filings/0001410578-25-001327.md) | [(854) d](/filings/0001410578-25-001820.md) | [(1,031) d](/filings/0001104659-25-112570.md) | [(1,168) d](/filings/0001104659-26-070987.md) | [(2,001)](/filings/0001104659-26-060353.md) | [(749) d](/filings/0001104659-26-095966.md) | [(1,195) d](/filings/0001104659-25-112570.md) | [(2,451) d](/filings/0001104659-26-070987.md) | [(1,683)](/filings/0001104659-26-060353.md) | [(875) d](/filings/0001104659-26-095966.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001410578-24-001891.md) | [0.0 d](/filings/0001410578-25-000518.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [6,988](/filings/0001410578-23-002492.md) | [300](/filings/0001410578-24-000887.md) | [295](/filings/0001410578-24-001448.md) | [428](/filings/0001410578-24-001891.md) | [1,037](/filings/0001410578-25-001327.md) | [1,207](/filings/0001410578-25-001820.md) | [1,207](/filings/0001104659-25-112570.md) | [1,393](/filings/0001104659-26-060353.md) | [1,565](/filings/0001104659-26-095966.md) | [2,550](/filings/0001104659-25-112570.md) | [7,699](/filings/0001104659-26-060353.md) | [7,472](/filings/0001104659-26-095966.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 7,483,242 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001104659-26-095966.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.